Abacavir and cardiovascular disease: A critical look at the data
Related Experiment Video
Updated: Mar 20, 2026
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
1Infectious Diseases and "Lluita contra la SIDA" Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain.
Insights
The risk of acute myocardial infarction (AMI) from abacavir in HIV patients remains unclear. While some studies show a link, others do not, necessitating further critical review of evidence.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacovigilance
Background:
- Abacavir and tenofovir are common HIV treatments.
- The cardiovascular safety of abacavir, specifically regarding acute myocardial infarction (AMI), is debated.
- Low AMI incidence in HIV populations complicates risk assessment.
Purpose of the Study:
- To critically review available evidence on the association between abacavir use and AMI risk in HIV-infected individuals.
- To address the controversy surrounding abacavir's cardiovascular safety.
- To inform clinical practice, especially with new abacavir-containing single-tablet regimens.
Main Methods:
- Review of observational cohort studies and meta-analyses of randomized clinical trials.
- Analysis of evidence considering potential biases, such as channelling or selection bias.
- Examination of recent cohort studies, including the NA-ACCORD study.
Main Results:
- Observational studies show conflicting results regarding abacavir and AMI risk.
- Meta-analyses of randomized trials found no association but lacked power to exclude small effects.
- Channelling bias in cohort studies may inflate cardiovascular risk in abacavir users.
- The NA-ACCORD study found no increased AMI risk in a fully adjusted model but suggested a possible association in treatment-naïve individuals.
Conclusions:
- The evidence on abacavir and AMI risk remains inconclusive.
- Further critical evaluation is needed due to conflicting data and potential biases.
- Clinical decisions should consider the evolving evidence, particularly for new combination therapies.
Abstract:
Most HIV-infected subjects will receive a treatment regimen including abacavir or tenofovir. Therefore, clarifying if there is an increased risk of acute myocardial infarction (AMI) among those exposed to abacavir is of the utmost importance. Due to the low frequency of AMI in this young population (2-5 per 1000 patients/year), efforts to clarify this have been quite controversial. While some observational cohorts have found a statistically significant association, others have not. Meta-analysis of randomized clinical trials offering the highest scientific evidence found no association at all, but with a limited statistical power to definitely rule out a small effect. A channelling or selection bias has been demonstrated in cohort studies, favouring the prescription of abacavir to subjects with or at risk for chronic kidney disease, and therefore, with an intrinsic increased cardiovascular risk. The recent NA-ACCORD cohort study does not identify an increased risk for AMI associated with recent abacavir use in a fully adjusted model (HR 1.33; 95%CI:0.96, 1.88). However, it does find an association in a second analysis restricted to treatment-naïve persons, with higher differences in baseline characteristics among compared arms. A critical review of the compiled available evidence is therefore mandatory, particularly in light of the first single-tablet regimen to receive approval that does contain abacavir.
Related Concept Videos
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:23Antihypertensive Drugs: Vasodilators
01:26Atherosclerosis III: Management
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors